Clinical Trials & Research

VANCOUVER, Washington, March 30, 2021 (GLOBE NEWSWIRE) – CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, is pleased to announce further results from its CD12 trial of severe-to-critically ill patients with COVID-19. Upon further statistical analysis of the critically

insights from industryDavid MaceChief Executive OfficerSwiftScale Biologics In this interview, News-Medical talks to David Mace, Chief Executive Officer at SwiftScale Biologics, about the work they do and how their partnership with Sartorius benefits both parties Please could you give an overview of SwiftScale, the work you do and your partnership with Sartorius? We are a

PRINCETON, N.J.–(BUSINESS WIRE) March 25, 2021 — Bristol Myers Squibb (NYSE: BMY) today announced primary results from the Phase 2/3 RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo (nivolumab) versus Opdivo alone in patients with previously untreated metastatic or unresectable melanoma. The trial met its primary endpoint of progression-free

How do different parts of the body communicate? Scientists at St. Jude are studying how signals sent from skeletal muscle affect the brain. The team studied fruit flies and cutting-edge brain cell models called organoids. They focused on the signals muscles send when stressed. The researchers found that stress signals rely on an enzyme called

London, UK 18 March 2021 – GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the first patient has been dosed in the SWIFT-2 trial as part of the phase 3 clinical programme investigating the safety and efficacy of GSK3511294 (“GSK’294”) in severe eosinophilic asthma (SEA). GSK’294 is an investigational medicine with potential to be the first biologic

Scientists at the Institute for Integrated Cell-Material Sciences (iCeMS) and colleagues in Japan have revealed molecular mechanisms involved in eliminating unwanted cells in the body. A nuclear protein fragment released into the cytoplasm activates a plasma membrane protein to display a lipid on the cell surface, signaling other cells to get rid of it. The

78.4% of women who continued on relugolix combination therapy remained responders (menstrual blood loss < 80 mL) through Week 76 compared with 15.1% of women who discontinued treatment at Week 52 (p < 0.0001) 69.8% of women who continued relugolix combination therapy remained responders through Week 104 88.3% of women who discontinued treatment relapsed with

Thought LeadersDr. Ewa JarockaSenior Research EngineerUmeå University Dr. Ewa Jarocka speaks to News-Medical about our senses, and how fingerprints can enhance our sense of touch. What provoked your research into our senses? We experience our surroundings through our sensory receptors. They are crucial for our survival, they allow us to interact with the outer world

FOSTER CITY, Calif. & KENILWORTH, N.J.–(BUSINESS WIRE)–Mar. 15, 2021– Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that they have entered into an agreement to co-develop and co-commercialize long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir, and Merck’s investigational nucleoside reverse transcriptase translocation inhibitor, islatravir, into a two-drug regimen with

Higher levels of the stomach-derived hormone ghrelin, which stimulates appetite, predict a greater preference for smaller immediate monetary rewards over larger delayed financial rewards, a new study finds. The study results will be presented at ENDO 2021, the Endocrine Society’s annual meeting. This research presents novel evidence in humans that ghrelin, the so-called “hunger hormone,”

16 March 2021 — Agreement builds on an earlier announcement that included support for the clinical development and supply of the treatment AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in late-stage development for the prevention and treatment

In a paper published in the Journal of General Internal Medicine, physician-researchers at Beth Israel Deaconess Medical Center (BIDMC) assessed the relative impact of COVID-19 on patients hospitalized with the viral infection in March and April 2020, versus patients hospitalized with influenza during the last five flu seasons at the medical center. Overall, the team

London, UK and Quebec City, Canada 16 March 2021 — Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to announce the start of Phase 3 clinical testing of Medicago’s plant-derived COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, as part of the ongoing Phase 2/3 study. Medicago received approval

A new study in Behavioral Ecology, published by Oxford University Press, finds that women are less likely to procreate in urban areas that have a higher percentage of females than males in the population. Although the majority modern cities have more women than men and thus suffer from lower fertility rates, the effects of female-biased

INDIANAPOLIS, March 16, 2021 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) announced today that mirikizumab met the primary and all key secondary endpoints in LUCENT-1, a 12-week Phase 3 induction study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderate to severe ulcerative colitis (UC). LUCENT-2, a multicenter, randomized, double-blind, placebo-controlled maintenance

A new study in Nicotine & Tobacco Research, published by Oxford University Press, finds that the use of high-strength nicotine e-cigarettes can help adults with schizophrenia spectrum disorders quit smoking. Some 60-90% of people with schizophrenia smoke cigarettes, compared to 15-24% of the general population. The researchers from the University of Catania, in collaboration with

GAITHERSBURG, Md., March 11, 2021 /PRNewswire/ – Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced final efficacy of 96.4% against mild, moderate and severe disease caused by the original COVID-19 strain in a pivotal Phase 3 trial in the United Kingdom (U.K.) of NVX–CoV2373, the company’s vaccine candidate. The company also announced the

INDIANAPOLIS, March 5, 2021 /PRNewswire/ — Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that The Lancet has published data from the pirtobrutinib (previously referred to as LOXO-305) global Phase 1/2 BRUIN clinical trial in relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and

Researchers based in India have demonstrated that horses inoculated with an inactivated dosage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are able to produce large amounts of strong antibodies that can neutralize multiple variants A pre-print version of the research paper is available to read in full on the bioRxiv*server. No time for horsing

MIAMI & KENILWORTH, N.J.–(BUSINESS WIRE) March 6, 2021 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics, LP today announced preliminary results from Ridgeback’s Phase 2a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and efficacy to eliminate SARS-CoV-2 viral RNA of molnupiravir (EIDD-2801/MK-4482), an investigational oral

Mar 11 2021 A new article has highlighted the need to improve diagnosis and treatment of one of the most common conditions affecting women worldwide – iron deficiency. Image Credit: The University of Western Australia “The misogyny of iron deficiency”, published today in Anesthesia to coincide with International Women’s Day, was written by researchers from

KENILWORTH, N.J.–(BUSINESS WIRE) March 8, 2021 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a Phase 1 study evaluating the safety, tolerability and pharmacokinetics (PK) of the company’s investigational subdermal drug-eluting implant with potential for extended administration of islatravir for pre-exposure prophylaxis (PrEP) of HIV-1 infection.

A study conducted by a team of researchers from Nanyang Technological University, Singapore (NTU Singapore) has found that Singaporeans, who scored high levels of empathy, would choose to prioritize the environment over the convenience and comfort of both themselves and their families or co-workers. Nearly eight out of ten (79%) respondents to a series of

BUFFALO, N.Y., March 01, 2021 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the company’s New

The global population is aging, and so are their eyes. In fact, the number of people with vision impairment and blindness is expected to more than double over the next 30 years. A meta-analysis in The Lancet Global Health, consisting of 48,000 people from 17 studies, found that those with more severe vision impairment had

PLYMOUTH MEETING, Pa., March 1, 2021 /PRNewswire/ – INOVIO, (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer and HPV-associated diseases, today announced it met primary and secondary endpoints among all evaluable subjects for the REVEAL 1 trial. This trial is one of

One of the hallmarks of chronic pain is inflammation, and scientists at the UNC School of Medicine have discovered that anti-inflammatory cells called MRC1+ macrophages are dysfunctional in an animal model of neuropathic pain. Returning these cells to their normal state could offer a route to treating debilitating pain caused by nerve damage or a

KENILWORTH, N.J.–(BUSINESS WIRE) March 1, 2021 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the company is voluntarily withdrawing the U.S. indication for Keytruda (pembrolizumab) for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least